2022 World Conference on Lung Cancer (Posters)-P1.15-05. Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)

P1.15-05. Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)

Back to course

Pdf Summary

The NintNivo trial aimed to evaluate the therapeutic potential of combining nivolumab (an immune checkpoint inhibitor) and nintedanib (an anti-angiogenisis agent) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have already received 1st or 2nd line treatment. The study enrolled 53 patients who received the combination therapy, with a dose finding phase to determine the recommended phase 2 dose (RP2D). The primary endpoints of the trial were safety and tolerability, as well as progression-free survival (PFS) after 6 and 9 months. Secondary endpoints included objective response rate (ORR), overall survival (OS), and duration of response (DoR). The interim analysis showed a median OS of 12.5 months and a 1-year OS rate of 53% for the treated patients. The PFS rate at 6 months was 24.5% and at 9 months was 10.5%. The objective response rate was 11.3%, with a median duration of response of 7.4 months. The combination therapy was generally well-tolerated, with common adverse events including diarrhea, nausea, fatigue, and weight decrease. Two grade 5 events were observed, both unrelated to the study medication. The results suggest that combining nivolumab and nintedanib may be a feasible and effective treatment option for patients with advanced non-squamous NSCLC who have already received prior treatment. Further analysis and exploration are planned to better understand the efficacy and benefits of this combination therapy.

Asset Subtitle

Martin Reck, Germany

Meta Tag

Speaker Martin Reck, Germany

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

NintNivo trial

therapeutic potential

nivolumab

nintedanib

non-squamous non-small cell lung cancer

advanced NSCLC

immune checkpoint inhibitor

anti-angiogenisis agent

progression-free survival

objective response rate